Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

G. Ottmann, Oliver; Dombret, Hervé; Martinelli, Giovanni; Simonsson, Bengt; Guilhot, François; A. Larson, Richard; Rege‐Cambrin, Giovanna; P. Radich, Jerald; Hochhaus, Andreas; Marie Apanovitch, Anne; Gollerkeri, Ashwin; Coutré, Steven

doi:10.1182/blood-2007-02-073528

Public

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

Published in Blood • May 11, 2007

Authors:

Oliver G. Ottmann

Hervé Dombret

Giovanni Martinelli

Abstract

Patients with Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL) have a rapid disease course and a poor prognosis. Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant or...

Subject

Dasatinib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!